Ask the Experts: Pneumococcal: Vaccine Products

Results (8)

One pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23, Merck) and two pneumococcal conjugate vaccines [PCV15 (Vaxneuvance, Merck), and PCV20 (Prevnar 20, Pfizer)] are FDA-licensed and recommended by CDC for use in the United States. PCV13 (Prevnar 13, Pfizer) is FDA-licensed and may still be available in some clinics. It is no longer routinely recommended; however, CDC guidance allows for its use as previously recommended in situations where PCV15 or 20 is indicated but unavailable and the alternative is that the patient would not be vaccinated.

PPSV23 is licensed for age 2 years and older. It was first licensed in 1983. It is an option for use in series with PCV15 for children and adults ages 2 through 64 years with specified risk factors for pneumococcal disease depending on their prior pneumococcal vaccination history. A PCV15 + PPSV23 series also is recommended as an option for pneumococcal disease prevention in adults 65 years and older. Following the 2022 changes to the pneumococcal vaccination schedule for adults, PPSV23 is no longer recommended alone, however PPSV23 is recommended for adults following PCV13 or PCV15 vaccination. It is not recommended for people who have previously received a PCV20 vaccination.

PCV15 is licensed for people age 6 weeks and older. CDC recommends the use of PCV15 as an option for the routine vaccination of children younger than age 5 years and certain children 6 through 18 years who have conditions that put them at high risk of invasive pneumococcal disease. CDC recommends PCV15 in series with PPSV23 as an option for pneumococcal disease prevention in adults age 19 through 64 years who are at increased risk for invasive pneumococcal disease due to behavioral or medical risk factors and for adults age 65 or older. When used in adults, it is always recommended to be used as part of a vaccination series with PPSV23 typically given 1 year later (a minimum interval of 8 weeks may be considered for people with immunocompromising medical conditions, cochlear implant or cerebrospinal fluid leak).

PCV20 is licensed for people age 6 weeks and older. CDC recommends the use of PCV20 as an option for the routine vaccination of children younger than 5 years of age and certain children 6 through 18 years who have conditions that put them at high risk of invasive pneumococcal disease. CDC recommends it as an option for pneumococcal disease prevention in adults age 19 through 64 years who are at increased risk for invasive pneumococcal disease due to behavioral or medical risk factors and for adults age 65 or older. If PCV20 is given, no further pneumococcal vaccination is recommended.

For details of recommendations for these vaccines, see Recommendations for Pneumococcal Vaccines Use in Children and Teens, www.immunize.org/wp-content/uploads/catg.d/p2016.pdf, or Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, PPSV23) to Adults: www.immunize.org/wp-content/uploads/catg.d/p3075.pdf.

Last reviewed: April 5, 2024

A polysaccharide vaccine is a type of vaccine that is composed of long chains of sugar molecules, called polysaccharides, that resemble the surface of certain serotypes of pneumococcal bacteria in order to help the immune system mount a response.

A conjugate vaccine is a type of vaccine that joins a protein to an antigen (in the case of pneumococcal vaccines, the protein is connected to unique polysaccharides from the surface of each of the pneumococcal serotypes). The protein helps improve the quality of the immune system response to the vaccine compared to the response to an unconjugated polysaccharide.

Last reviewed: April 5, 2024

The polysaccharide vaccine includes the different polysaccharides (chains of complex sugars) from different serotypes as the antigen. The conjugate vaccines have the polysaccharides for different serotypes attached (or conjugated) to a carrier protein. The immune response to the PPSV23 vaccine is a T-cell independent immune response, while the immune response to PCV vaccination is a T-cell dependent response that produces memory B-cells and reduces carriage of the bacteria in the respiratory track. The PPSV23 does not reduce bacterial carriage.

Last reviewed: April 5, 2024

FDA licensed the first pneumococcal conjugate vaccine against seven serotypes (PCV7, Prevnar7, Pfizer) in 2000. A large clinical trial showed PCV7 reduced invasive disease caused by vaccine serotypes by 97%. Compared to unvaccinated children, children who received PCV7:

  • Had 20% fewer episodes of chest X-ray confirmed pneumonia
  • Had 7% fewer episodes of acute otitis media
  • Underwent 20% fewer tympanostomy tube placements

FDA licensed PCV13 based on studies comparing the serologic response of children who received PCV13 to those who received PCV7. Substantial evidence demonstrates that routine infant PCV7 and PCV13 vaccination reduces the carriage and transmission of vaccine serotypes.

Researchers conducted a randomized placebo-controlled trial (CAPiTA trial) in the Netherlands among approximately 85,000 adults 65 years or older from 2008 through 2013. This trial evaluated the clinical benefit of PCV13 in the prevention of pneumococcal pneumonia. The results of the CAPiTA trial demonstrated:

  • 46% efficacy against vaccine-type pneumococcal pneumonia
  • 45% efficacy against vaccine-type non-bacteremic pneumococcal pneumonia
  • 75% efficacy against vaccine-type invasive pneumococcal disease (IPD, i.e., bacteremia or meningitis)

FDA licensed PCV15 and PCV20 in 2021 based on studies comparing the serologic response of adults who received either PCV15 or PCV20 to those who received PCV13. These studies showed PCV15 and PCV20 induced antibody levels comparable to those induced by PCV13 and shown to be protective against invasive disease. FDA subsequently expanded the indication for use of PCV15 and PCV20 to include children starting at age 6 weeks in 2022 and 2023, respectively, based on serologic studies.

Last reviewed: April 5, 2024

According to CDC, more than 80% of healthy adults who receive PPSV23 develop antibodies against the serotypes contained in the vaccine that persist for at least 5 years. Older adults and people with some chronic illnesses or immunodeficiency may not respond as well and their antibody levels may decline more quickly.

Overall, the vaccine is 60% to 70% effective in preventing invasive pneumococcal disease caused by serotypes in the vaccine. PPSV23 shows less effectiveness among immunocompromised people; however, because of their increased risk of invasive pneumococcal disease, CDC recommends PPSV23 for people in these groups who receive PCV15. There has not been consensus regarding the ability of PPSV23 to prevent non-bacteremic pneumococcal pneumonia; however, recent observational studies reported 21%–46% effectiveness against PPSV23-type pneumococcal pneumonia when PPSV23 was given less than 5 years before illness onset.

Unlike conjugate vaccines, PPSV23 vaccination has not been shown to decrease nasal carriage of pneumococcal bacteria among those vaccinated.

Last reviewed: April 5, 2024

The recommendations for pneumococcal vaccination of children and adults vary depending upon the specific vaccines available, and the recipient’s age, pneumococcal vaccination history, and medical or behavioral risk factors. CDC has summarized all of its recommendations at this site: www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html.

CDC has created an app for pneumococcal vaccine evaluation of individual patients. For more information, or to learn how to download the PneumoRecs VaxAdvisor mobile app, visit www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html.

Recommendations are summarized by Immunize.org in the following resources:

Last reviewed: April 5, 2024

S. pneumoniae bacteria are serotyped based on the polysaccharides in the outer capsule of the bacteria. Serotypes vary in how common they are and in what percentage of pneumococcal disease they cause.

Among the PCV vaccines, PCV13 includes serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. PCV15 includes all PCV13 serotypes plus 22F and 33F. PCV20 includes all PCV15 serotypes plus 8, 10A, 11A, 12F, and 15B. PPSV23 vaccine does not contain serotype 6A or 19A, but contains 19 other serotypes present in PCV20, plus serotypes 2, 9N, 17F, and 20.

1 2 3 4 5 6A 6B 7F 8 9N 9V 10A 11A 12F 14 15B 17F 18C 19A 19F 20 22F 23F 33F
PCV13 x   x x x x x x     x       x     x x x     x  
PCV15 x   x x x x x x     x       x     x x x   x x x
PCV20 x   x x x x x x x   x x x x x x   x x x   x x x
PPSV23 x x x x x   x x x x x x x x x x x x   x x x x x
Last reviewed: April 5, 2024

PCV vaccines are recommended to be given first because this sequence provides the best immune response to both PCV and PPSV23 vaccines. An evaluation of immune response after a second pneumococcal vaccination administered 1 year after an initial dose showed that subjects who received PPSV23 as the initial dose had lower antibody responses after subsequent administration of PCV13 than those who had received PCV13 as the initial dose followed by a dose of PPSV23. Lower antibody responses were also seen in people 65 years and older who received PCV20 1 to 5 years after a dose of PPSV23 compared to those who received PCV20 at least 6 months after a dose of PCV13 or those who received PCV13 followed by PPSV23.

Last reviewed: April 5, 2024

This page was updated on .

Our Affiliated Sites

For the Public: VaccineInformation.org
For Coalitions: ImmunizationCoalitions.org
65+ Flu Defense
Protect vulnerable, older adult patients from influenza.
Give2MenACWY.org
Improve protection from meningococcal serogroups ACWY.
Mass Vaccination Resources
Access guidance documents, toolkits, and helpful resources.
NAIIS
Home of the National Adult and Influenza Immunization Summit.